Advertisement
Advertisement

XFOR

XFOR logo

X4 Pharmaceuticals, Inc. Common Stock

3.92
USD
Sponsored
+0.07
+1.95%
Jul 27, 13:42 UTC -4
Open

XFOR Earnings Reports

Positive Surprise Ratio

XFOR beat 19 of 33 last estimates.

58%

Next Report

Date of Next Report
Aug 06, 2026
Estimate for Q2 26 (Revenue/ EPS)
$2.47M
/
-$0.18
Implied change from Q1 26 (Revenue/ EPS)
-8.85%
/
+12.50%
Implied change from Q2 25 (Revenue/ EPS)
+25.11%
/
-94.81%

X4 Pharmaceuticals, Inc. Common Stock earnings per share and revenue

On May 06, 2026, XFOR reported earnings of -0.16 USD per share (EPS) for Q1 26, beating the estimate of -0.20 USD, resulting in a 21.57% surprise. Revenue reached 2.71 million, compared to an expected 3.26 million, with a -17.03% difference. The market reacted with a +4.29% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 5 analysts forecast an EPS of -0.18 USD, with revenue projected to reach 2.47 million USD, implying an increase of 12.50% EPS, and decrease of -8.85% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
NovoCure Limited Ordinary Shares
Report Date
Jul 23, 2026 For Q2 26
Estimate
-$0.33
Actual
-$0.13
Surprise
+61.70%
logo
DBV Technologies S.A.
Report Date
Jul 16, 2026 For Q2 26
Estimate
-$0.10
Actual
-$0.60
Surprise
-494.06%
logo
argenx SE - ADR
Report Date
Jul 23, 2026 For Q2 26
Estimate
$6.29
Actual
$7.32
Surprise
+16.38%
logo
Lexaria Bioscience Corp. Common Stock
Report Date
Jul 13, 2026 For Q3 26
Estimate
-$0.08
Actual
-$0.08
Surprise
+7.73%
logo
VivoSim Labs, Inc. Common Stock
Report Date
Jul 14, 2026 For Q4 25
Estimate
-$0.19
Actual
-$2.21
Surprise
-1,040.35%
FAQ
For Q1 2026, X4 Pharmaceuticals, Inc. Common Stock reported EPS of -$0.16, beating estimates by 21.57%, and revenue of $2.71M, -17.03% below expectations.
The stock price moved up 4.29%, changed from $4.20 before the earnings release to $4.38 the day after.
The next earning report is scheduled for Aug 06, 2026.
Based on 5 analysts, X4 Pharmaceuticals, Inc. Common Stock is expected to report EPS of -$0.18 and revenue of $2.47M for Q2 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement